Trodelvy 180Mg Injection

₹ 0.00~~₹ 0.00~~

Brand: Trodelvy

Generic: Sacituzumab Govitecan-hziy

Manufacturer: Pfizer

Drug class: antibody-drug conjugates (ADCs), specifically functioning as a Trop-2-directed antibody and topoisomerase inhibitor conjugate.

Description

Introduction to Trodelvy 180mg Injection

Trodelvy 180mg Injection contains sacituzumab govitecan-hziy. It is an anti-cancer medicine developed by Gilead Sciences and belongs to a group of medicines called antibody-drug conjugates (ADCs).

Trodelvy is used to treat certain types of advanced breast cancer and urothelial cancer in adults who have received previous cancer treatments.

It works by targeting a protein called Trop-2, which is found in high amounts on many cancer cells. After attaching to the cancer cell, Trodelvy enters the cell and releases SN-38, a medicine that damages the cancer cell and helps stop its growth.

Trodelvy 180mg Injection is given as an intravenous (IV) infusion by a healthcare professional at a hospital or cancer treatment centre.

Uses of Trodelvy 180mg Injection

Trodelvy 180mg Injection is used to treat:

Triple-negative breast cancer (TNBC): Used in adults with unresectable locally advanced or metastatic TNBC who have received two or more previous systemic cancer treatments.
HR-positive, HER2-negative breast cancer: Used in adults with metastatic breast cancer after endocrine-based treatment and at least two other systemic therapies.
Urothelial cancer: Used in adults with locally advanced or metastatic urothelial cancer who have previously received platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor.

The exact treatment and duration will be decided by your doctor based on your condition and previous treatments.

Storage

Store Trodelvy vials in a refrigerator at 2°C to 8°C.
Do not freeze the medicine.
Keep the vial in its original carton to protect it from light.
After preparation, the diluted medicine should be used within the time recommended by the healthcare professional and product instructions.
Keep Trodelvy out of the reach of children.

Safety Advice

Pregnancy

Consult Your Doctor

Trodelvy may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for at least 6 months after the last dose.

Tell your doctor if you are pregnant, planning to become pregnant, or think you may be pregnant.

Breastfeeding

Consult Your Doctor

Do not breastfeed while receiving Trodelvy and for at least 1 month after the last dose. Talk to your doctor about safe feeding options during this period.

Lungs

Consult Your Doctor

Tell your doctor immediately if you develop a new or worsening cough, difficulty breathing, shortness of breath, or chest pain during treatment. These symptoms may require prompt medical attention.

Liver

Consult Your Doctor

Tell your doctor if you have liver problems. Trodelvy may increase exposure to its active drug component in patients with liver impairment and may increase the risk of side effects. Your doctor may monitor your liver function during treatment.

Alcohol

Consult Your Doctor

Talk to your doctor before consuming alcohol during treatment. Alcohol may worsen symptoms such as nausea, tiredness, or dizziness.

Driving

Consult Your Doctor

Trodelvy may cause tiredness, dizziness, or nausea in some people. Avoid driving or operating machinery if you experience these effects or if you do not feel alert.

FAQ

What is Trodelvy 180mg Injection used for?

Trodelvy 180mg Injection is used to treat certain types of cancer in adults. It may be prescribed for triple-negative breast cancer (TNBC), HR-positive/HER2-negative breast cancer, and urothelial cancer that has spread or cannot be treated with surgery. It is generally used after previous cancer treatments.

How does Trodelvy 180mg Injection work?

Trodelvy contains sacituzumab govitecan, an antibody-drug conjugate (ADC). It targets a protein called Trop-2 found on many cancer cells and delivers the chemotherapy medicine SN-38 into these cells. SN-38 damages the DNA of cancer cells and helps stop them from growing and causes them to die.

What is Trop-2?

Trop-2 (trophoblast cell-surface antigen 2) is a protein found on the surface of many cancer cells, including breast and urothelial cancer cells. Trodelvy targets this protein to help deliver its cancer-fighting medicine to the cancer cells.

How is Trodelvy 180mg Injection administered?

Trodelvy 180mg Injection is given through an intravenous (IV) infusion by a healthcare professional. The first infusion usually takes about 3 hours. If it is well tolerated, later infusions may take about 1 to 2 hours. Trodelvy is usually given on Day 1 and Day 8 of a 21-day treatment cycle, as prescribed by the doctor.

What are the common side effects of Trodelvy?

Common side effects of Trodelvy may include low white blood cell counts (neutropenia), nausea, diarrhea, tiredness, anemia, vomiting, hair loss, and abdominal pain. Low white blood cell counts and diarrhea are important side effects that may require medical monitoring and treatment.